drugset / Trial / NCT01873885

Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomera™ (PB1046) in Adult Subjects With Stage 1 or 2 Essential Hypertension

NCT01873885 ↗

Phase 1 Completed 20 enrolled PhaseBio Pharmaceuticals Inc.
RandomizedSingle-groupTriple-blindTreatment

Summary

This study is an exploratory Phase 1 randomized, double-blind (Investigator and study subject and 2-D echo endpoint assessor), placebo-controlled single IV infusion dose escalation study that will enroll up to approximately 32 subjects with stage 1 or 2 essential hypertension.

Timeline

Start
2013-06
Primary completion
2014-03
Completion
2014-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Pemziviptadil Peptide 0.005 mg/kg Intravenous
Subject Pemziviptadil Peptide 0.01 mg/kg Intravenous
Subject Pemziviptadil Peptide 0.02 mg/kg Intravenous